- Home
- ADAP vs CMMB Comparison
ADAP vs CMMB Comparison
Compare ADAP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- CMMB
- Stock Information
- Founded
- ADAP 2008
- CMMB 2004
- Country
- ADAP United Kingdom
- CMMB Israel
- Employees
- ADAP N/A
- CMMB N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- CMMB Health Care
- Exchange
- ADAP Nasdaq
- CMMB Nasdaq
- Market Cap
- ADAP 21.3M
- CMMB 22.0M
- IPO Year
- ADAP 2015
- CMMB N/A
- Fundamental
- Price
- ADAP $0.06
- CMMB $3.03
- Analyst Decision
- ADAP Hold
- CMMB Strong Buy
- Analyst Count
- ADAP 6
- CMMB 2
- Target Price
- ADAP $1.02
- CMMB $26.50
- AVG Volume (30 Days)
- ADAP 62.3M
- CMMB 142.4K
- Earning Date
- ADAP 11-12-2025
- CMMB 11-13-2025
- Dividend Yield
- ADAP N/A
- CMMB N/A
- EPS Growth
- ADAP N/A
- CMMB N/A
- EPS
- ADAP N/A
- CMMB N/A
- Revenue
- ADAP $65,084,999.00
- CMMB N/A
- Revenue This Year
- ADAP N/A
- CMMB N/A
- Revenue Next Year
- ADAP $52.35
- CMMB N/A
- P/E Ratio
- ADAP N/A
- CMMB N/A
- Revenue Growth
- ADAP N/A
- CMMB N/A
- 52 Week Low
- ADAP $0.04
- CMMB $2.96
- 52 Week High
- ADAP $1.17
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- ADAP 38.42
- CMMB 26.72
- Support Level
- ADAP $0.06
- CMMB $2.96
- Resistance Level
- ADAP $0.07
- CMMB $3.14
- Average True Range (ATR)
- ADAP 0.01
- CMMB 0.22
- MACD
- ADAP 0.01
- CMMB 0.01
- Stochastic Oscillator
- ADAP 53.33
- CMMB 8.09
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.